Review ArticleExpert Review
Open Access

What Is Allopurinol Failure and What Should We Do About It?

Lisa K. Stamp and Nicola Dalbeth
The Journal of Rheumatology June 2024, 51 (6) 556-562; DOI: https://doi.org/10.3899/jrheum.2024-0144

REFERENCES

  1. 1.↵
    1. Bursill D,
    2. Taylor WJ,
    3. Terkeltaub R, et al.
    Gout, hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis 2019;78:1592-600.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Landgren AJ,
    2. Jacobsson LTH,
    3. Lindström U, et al.
    Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study. Arthritis Res Ther 2017;19:173.
    OpenUrl
  3. 3.↵
    1. Dalbeth N,
    2. Billington K,
    3. Doyle A, et al.
    Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial. Arthritis Rheumatol 2019;71:1739-46.
    OpenUrl
  4. 4.↵
    1. Stamp LK,
    2. Frampton C,
    3. Morillon MB, et al.
    Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol 2022;4:e53-60.
    OpenUrl
  5. 5.↵
    1. Perez-Ruiz F,
    2. Calabozo M,
    3. Pijoan JI,
    4. Herrero-Beites AM,
    5. Ruibal A.
    Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. FitzGerald JD,
    2. Dalbeth N,
    3. Mikuls T, et al.
    2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res 2020;72:744-60.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Richette P,
    2. Doherty M,
    3. Pascual E, et al.
    2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29-42.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Hui M,
    2. Carr A,
    3. Cameron S, et al.
    The British Society for Rheumatology guideline for the management of gout. Rheumatology 2017;56:e1-e20.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Son CN,
    2. Stewart S,
    3. Su I,
    4. Mihov B,
    5. Gamble G,
    6. Dalbeth N.
    Global patterns of treat-to-serum urate target care for gout: systematic review and meta-analysis. Semin Arthritis Rheum 2021;51:677-84.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Collins
    . Successful. [Internet. Accessed March 7, 2024.] Available from: https://www.collinsdictionary.com/dictionary/englishsuccessful
  11. 11.↵
    1. de Lautour H,
    2. Taylor WJ,
    3. Adebajo A, et al.
    Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises. Arthritis Care Res 2016;68:667-72.
    OpenUrl
  12. 12.↵
    1. Figueras A,
    2. Laporte JR.
    Failures of the therapeutic chain as a cause of drug ineffectiveness. BMJ 2003;326:895-6.
    OpenUrlFREE Full Text
  13. 13.↵
    1. Clark F.
    Rise in online pharmacies sees counterfeit drugs go global. Lancet 2015;386:1327-8.
    OpenUrlCrossRef
  14. 14.↵
    1. ASOP Global Foundation
    . 2021 American perceptions and use of online pharmacies. [Internet. Accessed March 7, 2024.] Available from: https://asopfoundation.pharmacy/wp-content/uploads/2021/07/ASOP-Global-Foundation-2021-Consumer-Behavior-Survey-Key-Findings_Final-7.9.2021.pdf
  15. 15.↵
    1. Becker MA,
    2. Fitz-Patrick D,
    3. Choi HK, et al.
    An open-label, 6-month study of allopurinol safety in gout: the lasso study. Semin Arthritis Rheum 2015;45:174-83.
    OpenUrl
  16. 16.↵
    1. Stamp LK,
    2. Chapman P,
    3. Hudson B,
    4. Frampton C,
    5. Hamilton G,
    6. Judd A.
    The challenges of managing gout in primary care: results of a best-practice audit. Aust J Gen Pract 2019;48:631-7.
    OpenUrl
  17. 17.↵
    1. Dalbeth N,
    2. Kumar S,
    3. Stamp LK,
    4. Gow P.
    Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Becker MA,
    2. Schumacher HR Jr,
    3. Wortmann RL, et al.
    Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Stamp LK,
    2. Chapman PT,
    3. Barclay ML, et al.
    A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 2017;76:1522-8.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Stamp LK,
    2. Chapman PT,
    3. Barclay M, et al.
    Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann Rheum Dis 2017;76:2065-70.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Doherty M,
    2. Jenkins W,
    3. Richardson H, et al.
    Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 2018;392:1403-12.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Stamp LK,
    2. Chapman PT,
    3. Barclay M, et al.
    The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized clinical trial. Arthritis Res Ther 2017;19:283.
    OpenUrl
  23. 23.↵
    1. Stamp LK,
    2. Taylor WJ,
    3. Jones PB, et al.
    Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529-36.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Hande KR,
    2. Noone RM,
    3. Stone WJ.
    Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Dalbeth N,
    2. Reid S,
    3. Stamp LK,
    4. Arroll B.
    Making the right thing the easy thing to do: strategies to improve outcomes in gout. Lancet Rheumatol 2019;1:e122-31.
    OpenUrl
  26. 26.↵
    1. Te Karu L,
    2. Arroll B,
    3. Bryant L,
    4. Harwood M,
    5. Kenealy T.
    The inequity of access to health: a case study of patients with gout in one general practice. N Z Med J 2021;134:51-8.
    OpenUrl
  27. 27.↵
    1. Emad Y,
    2. Dalbeth N,
    3. Weinman J,
    4. Chalder T,
    5. Petrie KJ.
    Why do patients with gout not take allopurinol? J Rheumatol 2022; 49:622-6.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Stamp LK,
    2. Barclay ML,
    3. O’Donnell JL, et al.
    Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther 2011;90:392-8.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Woodward OM,
    2. Köttgen A,
    3. Coresh J,
    4. Boerwinkle E,
    5. Guggino WB,
    6. Köttgen M.
    Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 2009;106:10338-42.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Wallace MC,
    2. Roberts RL,
    3. Nanavati P, et al.
    Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology 2018;57:656-60.
    OpenUrl
  31. 31.↵
    1. Stamp LK,
    2. Barclay ML,
    3. O’Donnell JL, et al.
    Furosemide increases plasma oxypurinol without lowering serum urate – a complex drug interaction: implications for clinical practice. Rheumatology 2012;51:1670-6.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Tatlock S,
    2. Rüdell K,
    3. Panter C, et al.
    What outcomes are important for gout patients? In-depth qualitative research into the gout patient experience to determine optimal endpoints for evaluating therapeutic interventions. Patient 2017;10:65-79.
    OpenUrl
  33. 33.↵
    1. Singh JA.
    Research priorities in gout: the patient perspective. J Rheumatol 2014;41:615-6.
    OpenUrlFREE Full Text
  34. 34.↵
    1. Stewart S,
    2. Guillen AG,
    3. Taylor WJ, et al.
    The experience of a gout flare: a meta-synthesis of qualitative studies. Semin Arthritis Rheum 2020;50:805-11.
    OpenUrl
  35. 35.↵
    1. Stamp L,
    2. Horne A,
    3. Mihov B, et al.
    Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Ann Rheum Dis 2023;82:1626-34.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Dalbeth N,
    2. Pool B,
    3. Gamble GD, et al.
    Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 2010;62:1549-56.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Cao C,
    2. Gamble G,
    3. Horne A, et al.
    The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy. Rheumatology 2023 Sept 9 (Epub ahead of print).
  38. 38.↵
    1. Dalbeth N,
    2. Doyle AJ,
    3. Billington K, et al.
    Intensive serum urate lowering with oral urate-lowering therapy for erosive gout: a randomized double-blind controlled trial. Arthritis Rheumatol 2022;74:1059-69.
    OpenUrl
  39. 39.↵
    1. Gutiérrez-Macías A,
    2. Lizarralde-Palacios E,
    3. Martínez-Odriozola P,
    4. Miguel-De la Villa F.
    Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 2005;331:623-4.
    OpenUrlFREE Full Text
  40. 40.↵
    1. Perry ME,
    2. Madhok R.
    Treatment failure gout: failure to treat? Rheumatology 2010;49:2233-4.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

ALLOPURINOL
GOUT

Keywords